Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials

C Bokemeyer, C Kollmannsberger, S Stenning, J T Hartmann, A Horwich, C Clemm, A Gerl, C Meisner, C-P Rückerl, H-J Schmoll, L Kanz, T Oliver, C Bokemeyer, C Kollmannsberger, S Stenning, J T Hartmann, A Horwich, C Clemm, A Gerl, C Meisner, C-P Rückerl, H-J Schmoll, L Kanz, T Oliver

Abstract

To study the role of single agent carboplatin chemotherapy in patients with metastatic seminoma based on the data from two randomised trials. In subgroup analyses in patients with different disease characteristics, the outcome treated with either single agent carboplatin or cisplatin-based combination chemotherapy was compared. Individual patient data from two randomised European trials involving patients with metastatic seminoma were gathered. The primary endpoint for all analyses was progression-free survival. The source data of 361 patients, 184 treated with cisplatin-based combinations and 177 treated with carboplatin single agent therapy, were entered into the analysis. Patient characteristics were comparable among the cisplatin-based and the carboplatin single agent treated patient groups with lymph nodes and lungs being the most frequent metastatic sites in 92 and 8% of patients, respectively. Overall, patients treated with single agent carboplatin had an inferior 5-year overall (89 and 94%; P=0.09) and progression-free survival rate (72 and 92%; P< 0.0001) compared with patients receiving cisplatin-based combinations. For all investigated subgroups (based on age, prior radiation therapy, metastatic sites), carboplatin single agent therapy was found to be inferior to cisplatin-based combination chemotherapy. In conclusion, carboplatin single agent therapy cannot be recommended as standard treatment for any patient subgroup with advanced metastatic seminoma and cisplatin-based combination regimens remain the standard of care.

Figures

Figure 1
Figure 1
Progression-free survival rates for patients from two randomised studies receiving either cisplatin-based combination chemotherapy or carboplatin single agent therapy for metastatic seminoma (n=361).
Figure 2
Figure 2
Overall survival for patients from two randomised studies receiving either cisplatin-based combination chemotherapy or carboplatin single agent therapy for metastatic seminoma (n=361).

References

    1. Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ, Scher HI, Geller NL, Fair WR, Herr H, Sogani P (1993) Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 11: 598–606
    1. Bokemeyer C, Kohrmann O, Tischler J, Weissbach L, Rath U, Haupt A, Schoffski P, Harstrick A, Schmoll HJ (1996) A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with ‘good-risk’ metastatic non-seminomatous germ cell tumors. Ann Oncol 7: 1015–1021
    1. Bosl GJ, Motzer RJ (1997) Medical progress: testicular germ-cell cancer. N Engl J Med 337: 242–253
    1. Clemm C, Bokemeyer C, Gerl A, Holzel D, Weissbach L, Bamberg M, Schoeffski P, Harstrick A, Schmoll HJ, Wilmanns W (2000) Randomized trial comparing cisplatin/etoposide/ifosfamide with carboplatin monochemotherapy in patients with advanced metastatic seminoma. Proc Am Soc Clin Oncol 19: 328 (abstract 1283)
    1. Clemm C, Gerl A, Kohl P, Hentrich M, Hartenstein R, Gassel WD, Knutzen B, Wilmanns W (1993) Combination chemotherapy containing cisplatin/ifosfamide and vinblastine or etoposide in bulky seminoma. Eur J Cancer 29A(Suppl 6): S240 (abstract 1347)
    1. Cox DR, Oakes D (1984) Analysis of survival data. London: Chapman and Hall
    1. Einhorn LH (1990) Treatment of testicular cancer: a new and improved model. J Clin Oncol 8: 1777–1781
    1. Fléchon A, Rivoire M, Biron P, Droz JP (2001) Importance of surgery as salvage treatment after high dose chemotherapy failure in germ cell tumors. J Urol 165: 1920–1926
    1. Horwich A, Dearnaley DP, A'Hern R, Mason M, Thomas G, Jay G, Nicholls J (1992) The activity of single-agent carboplatin in advanced seminoma. Eur J Cancer 28A: 1307–1310
    1. Horwich A, Oliver RT, Wilkinson PM, Mead GM, Harland SJ, Cullen MH, Roberts JT, Fossa SD, Dearnaley DP, Lallemand E, Stenning SP (2000) A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party. Br J Cancer 83: 1623–1629
    1. Horwich A, Sleijfer DT, Fossa SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, de Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP (1997) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15: 1844–1852
    1. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. Am J Stat Assoc 53: 457–481
    1. Mead G, for the International Germ Cell Cancer Collaborative Group (1997) International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 15: 594–603
    1. Oliver RT, Lore S, Ong J (1990) Alternatives to radiotherapy in the management of seminoma. Br J Urol 65: 61–67
    1. Schmoll HJ, Harstrick A, Bokemeyer C, Dieckmann KP, Clemm C, Berdel WE, Souchon R, Schober C, Wilke H, Poliwoda H (1993) Single-agent carboplatinum for advanced seminoma. A phase II study. Cancer 72: 237–243

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit